Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GALR2 | O43603 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405563 | 0.94 | MAPT (0.51) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL5606205 | 0.89 | MAPT (0.49) | SLC9A1MAPTKMT2AHTTALDH1A1 | |
| SCHEMBL8513944 | 0.89 | MAPT (0.55) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL2972082 | 0.88 | SLC9A1 (0.60) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL27796244 | 0.87 | SLC9A1 (0.56) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL14903460 | 0.87 | RECQL (0.57) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL29725300 | 0.87 | RECQL (0.57) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL10936842 | 0.85 | MAPT (0.55) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL11252461 | 0.83 | MAPT (0.50) | SLC9A1MAPTNPSR1KMT2AHTT | |
| SCHEMBL21989034 | 0.83 | SLC9A1 (0.52) | SLC9A1MAPTNPSR1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| CN-102176825-A | Flavin derivatives | BIORELIX PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-1089982-B1 | METHODS OF INHIBITING CORROSION USING ISOMERS OF CHLORO-METHYLBENZOTRIAZOLE | BETZDEARBORN INC (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1089982-A4 | METHODS OF INHIBITING CORROSION USING ISOMERS OF CHLORO-METHYLBENZOTRIAZOLE | BETZDEARBORN INC (US) | 2005-04-06 | — | — | EP | disclosed |
| CN-1184210-C | Methods of inhibiting corrosion using isomers of chloro-methylbenzotrazole | BETZDEARBORN INC (US) | 2005-01-12 | — | — | CN | disclosed |
| CN-1306517-A | Methods of inhibiting corrosion using isomers of chloro-methylbenzotrazole | BETZDEARBORN INC (US) | 2001-08-01 | — | — | CN | disclosed |
| EP-1089982-A1 | METHODS OF INHIBITING CORROSION USING ISOMERS OF CHLORO-METHYLBENZOTRIAZOLE | BetzDearborn Inc (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067222-A1 | METHODS OF INHIBITING CORROSION USING ISOMERS OF CHLORO-METHYLBENZOTRIAZOLE | BETZDEARBORN INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5968408-A | ODORLESS | BETZDEARBORN INC. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | SLC9A1 3718/4885MAPT 4674/4885NPSR1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.